Zacks: Analysts Anticipate Myriad Genetics, Inc. (MYGN) Will Announce Quarterly Sales of $221.45 Million
Wall Street analysts forecast that Myriad Genetics, Inc. (NASDAQ:MYGN) will announce sales of $221.45 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Myriad Genetics’ earnings. The lowest sales estimate is $219.78 million and the highest is $226.34 million. Myriad Genetics posted sales of $200.90 million in the same quarter last year, which suggests a positive year-over-year growth rate of 10.2%. The business is scheduled to issue its next earnings report on Tuesday, August 20th.
On average, analysts expect that Myriad Genetics will report full year sales of $857.62 million for the current fiscal year, with estimates ranging from $855.52 million to $862.04 million. For the next year, analysts anticipate that the business will report sales of $920.83 million, with estimates ranging from $909.00 million to $936.79 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Myriad Genetics.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.34 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.38 by ($0.04). The firm had revenue of $216.60 million for the quarter, compared to the consensus estimate of $217.76 million. Myriad Genetics had a net margin of 2.62% and a return on equity of 9.82%. The company’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.34 earnings per share.
Shares of NASDAQ:MYGN traded up $0.44 during mid-day trading on Tuesday, reaching $24.77. 1,143,948 shares of the company traded hands, compared to its average volume of 1,231,837. The company has a market cap of $1.79 billion, a PE ratio of 20.64, a price-to-earnings-growth ratio of 1.46 and a beta of 0.55. The company has a current ratio of 3.15, a quick ratio of 2.86 and a debt-to-equity ratio of 0.24. Myriad Genetics has a 52 week low of $23.08 and a 52 week high of $50.44.
In related news, insider Ralph L. Mcdade sold 1,975 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $31.00, for a total value of $61,225.00. Following the transaction, the insider now directly owns 122,604 shares of the company’s stock, valued at approximately $3,800,724. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 5.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. New York State Teachers Retirement System lifted its holdings in Myriad Genetics by 0.6% in the 1st quarter. New York State Teachers Retirement System now owns 50,798 shares of the company’s stock worth $1,686,000 after purchasing an additional 307 shares in the last quarter. Mason Street Advisors LLC lifted its holdings in Myriad Genetics by 1.4% in the 1st quarter. Mason Street Advisors LLC now owns 23,532 shares of the company’s stock worth $781,000 after purchasing an additional 315 shares in the last quarter. LeJeune Puetz Investment Counsel LLC lifted its holdings in Myriad Genetics by 1.6% in the 4th quarter. LeJeune Puetz Investment Counsel LLC now owns 24,925 shares of the company’s stock worth $725,000 after purchasing an additional 400 shares in the last quarter. Taylor Frigon Capital Management LLC raised its holdings in shares of Myriad Genetics by 1.2% during the 4th quarter. Taylor Frigon Capital Management LLC now owns 40,426 shares of the company’s stock worth $1,175,000 after acquiring an additional 497 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in shares of Myriad Genetics by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 28,955 shares of the company’s stock worth $961,000 after acquiring an additional 523 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Further Reading: How to interpret the current ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.